MediTrust Health and Sino Biopharm partnered to boost access to affordable, innovative drugs via AI-driven insurance integration at the 2025 China Expo.

At the 2025 China International Import Expo, MediTrust Health and Sino Biopharm signed a strategic agreement to advance drug-insurance integration, aiming to improve access to innovative, affordable medicines. The partnership combines pharmaceutical innovation with commercial health insurance, using AI and data to streamline diagnosis, treatment, and payment. Sino Biopharm, with over 120 pipeline drugs and RMB 30 billion in annual revenue, highlighted insurance’s role in supporting sustainable R&D. MediTrust Health, serving 393 million policies across 160 cities by late 2024, reported RMB 6.7 billion in patient cost savings. The initiative supports China’s “Healthy China 2030” strategy by creating a more efficient, patient-centered healthcare ecosystem.